Clinical Trial Update: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets [Phase 1]

View source ↗

Summary

An update on a Phase 1 study evaluating ABBV-453 in adults with relapsed or refractory multiple myeloma, focusing on adverse events and changes in disease activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• ABBV-453

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING